Search Results:

27th May

Chloroquine and it’s analogue hydrochloroquine were proposed as candidate therapeutics against COVID-19, and were one of the drug regiments tested in the World Health Organisation (WHO) Solidarity Trial. However, on the 26th May 2020 the WHO announced the suspension of chloroquine/hydrochloroquine trials for COVID-19.

14th April

In 2005, after the 2002-3 SARS epidemic researchers demonstrated the in-vivo anti-viral effect of chloroquine in primate cell lines infected with SARS-CoV. These results were further confirmed by Gao et al., Wang et al., & Liu et al.., who also showed inhibitory effects of chloroquine on SARS-CoV-2, the etiological agent of COVID-19.

05 June 2023

In a recent paper, scientists have discovered a drug resistance mechanism in one of the most dangerous malaria parasites affecting humans…

9th October

Molecular mimicry drives the pathogenesis of autoimmune neuropathies such as Guillain-Barré syndrome and multiple sclerosis.Does molecular mimicry also play a role in COVID-19 pathogenesis?

18th August

Hoffman et al., demonstrated that (hydroxy)chloroquine inhibited viral entry in Vero (kidney-derived) cell-lines that did not express TMPRSS2, but had no inhibitory effect on Vero cells-lines that expressed TMPRSS2. Additionally, (hydroxy)chloroquine had limited effect on SARS-CoV-2 entry into TMPRSS2-expressing lung cell-lines.

In a short span of time, COVID-19 has become a rapidly spreading communicable disease forcing the WHO to declare it as the “Public Health Emergency of International Concern” on January 30. As of April 16, the WHO pandemic update indicates a whopping 1,991,562 confirmed reported cases…

3rd April

In an attempt to avoid repeating the mistakes of the 2014–16 West African Ebola epidemic, where clinical trials were set up late, leading to the under-recruiting of patients – in the current pandemic researchers have decided to start trials as soon as possible…

1st April

In an unprecedented effort to obtain scientific data during the SARS-CoV-2 pandemic, the World Health Organization (WHO) has announced the new SOLIDARITY trial that would include thousands of patients from around the world (45 countries and counting)…

18th March

Our second highlight is on talks that focused on understanding malaria parasite transmission, motility and emergence of anti-malarial resistance, as well as the neutrophil activity in malaria friend or foe. Prof. Frischknech (Ruprecht-Karis University, Heidelberg) gave a lecture on ‘’Transmission of malaria – from microscopy to experimental vaccine studies’’.

Immune Response to HIV Vaccine Candidates The most efficacious HIV vaccine candidate to date was the RV144 vaccine run in a trial in Thailand – with 31.5% efficacy. Although the trial showed very modest efficacy, and was based on small numbers, it provided important knowledge towards making a more effective vaccine. Based on the results, Read More